Arginine Therapy for Sickle Cell Disease Acute Pain Episodes
https://jamanetwork.com/journals/jama/fullarticle/2853065
This randomized trial assesses the effect of arginine therapy on time to crisis resolution among children and young adults experiencing sickle cell disease (SCD)–related acute pain episodes.
https://jamanetwork.com/journals/jama/fullarticle/2853065
This randomized trial assesses the effect of arginine therapy on time to crisis resolution among children and young adults experiencing sickle cell disease (SCD)–related acute pain episodes.
Ventricular Fibrillation With Intravascular Lithotripsy
https://jamanetwork.com/journals/jamacardiology/fullarticle/2852978
This case report discusses intravascular lithotripsy and resultant ventricular fibrillation in a man in his 70s with severely calcified right coronary artery stenosis.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2852978
This case report discusses intravascular lithotripsy and resultant ventricular fibrillation in a man in his 70s with severely calcified right coronary artery stenosis.
❤1
Clarifications in JAMA Clinical Guidelines Synopsis
https://jamanetwork.com/journals/jama/fullarticle/2853154
In the JAMA Clinical Guidelines Synopsis titled “Antiviral Therapies for Adults With Mild to Moderate COVID-19 Infection,” published online June 30, 2026, several points were rewritten for clarification. In the third paragraph of the Evidence Base section, the second sentence was revised to “Coadministration of nirmatrelvir-ritonavir is contraindicated with certain medications due to risk of serious or fatal toxicity (eg, amiodarone, statins [especially simvastatin and lovastatin], phosphodiesterase 5 inhibitors [eg, sildenafil], α-blockers [eg, tamsulosin], or benzodiazepines [eg, triazolam, midazolam]) or strong CYP3A inducers (eg, rifampin, carbamazepine, St John’s wort).” In the fifth paragraph of the Evidence Base section, the last sentence was revised to “Patients who can become pregnant should use contraception during molnupiravir use and for 4 days following the last dose if their partner did not also use molnupiravir. Individuals with a male partner who used molnupiravir should use effective contraception for 3 months after the last dose. Patients who are breastfeeding should consider interrupting breastfeeding and instead pump and discard breast milk during treatment with molnupiravir and for 4 days after the last dose.” In the second paragraph of the Discussion section, an additional sentence was added regarding molnupiravir: “It is currently available in the US only through Emergency Use Authorization, although the authorization will be terminated effective June 29, 2027.” This article was corrected online.
https://jamanetwork.com/journals/jama/fullarticle/2853154
In the JAMA Clinical Guidelines Synopsis titled “Antiviral Therapies for Adults With Mild to Moderate COVID-19 Infection,” published online June 30, 2026, several points were rewritten for clarification. In the third paragraph of the Evidence Base section, the second sentence was revised to “Coadministration of nirmatrelvir-ritonavir is contraindicated with certain medications due to risk of serious or fatal toxicity (eg, amiodarone, statins [especially simvastatin and lovastatin], phosphodiesterase 5 inhibitors [eg, sildenafil], α-blockers [eg, tamsulosin], or benzodiazepines [eg, triazolam, midazolam]) or strong CYP3A inducers (eg, rifampin, carbamazepine, St John’s wort).” In the fifth paragraph of the Evidence Base section, the last sentence was revised to “Patients who can become pregnant should use contraception during molnupiravir use and for 4 days following the last dose if their partner did not also use molnupiravir. Individuals with a male partner who used molnupiravir should use effective contraception for 3 months after the last dose. Patients who are breastfeeding should consider interrupting breastfeeding and instead pump and discard breast milk during treatment with molnupiravir and for 4 days after the last dose.” In the second paragraph of the Discussion section, an additional sentence was added regarding molnupiravir: “It is currently available in the US only through Emergency Use Authorization, although the authorization will be terminated effective June 29, 2027.” This article was corrected online.
Resurgence of Malaria in Ethiopia
https://jamanetwork.com/journals/jama/fullarticle/2853152
This study examines whether emerging drug and diagnostic resistance variants are contributing to Ethiopia’s malaria resurgence.
https://jamanetwork.com/journals/jama/fullarticle/2853152
This study examines whether emerging drug and diagnostic resistance variants are contributing to Ethiopia’s malaria resurgence.
Audio Highlights August 21, 2026
https://jamanetwork.com/journals/jama/fullarticle/2853372
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
https://jamanetwork.com/journals/jama/fullarticle/2853372
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
Gestational Hypertension Has Increased, Affecting 1 in 10 Pregnancies
https://jamanetwork.com/journals/jama/fullarticle/2853283
The incidence of gestational hypertension increased by 73% from 2016 to 2024, according to a report from the US Centers for Disease Control and Prevention (CDC) National Vital Statistics System.
https://jamanetwork.com/journals/jama/fullarticle/2853283
The incidence of gestational hypertension increased by 73% from 2016 to 2024, according to a report from the US Centers for Disease Control and Prevention (CDC) National Vital Statistics System.
FDA Approves First Freeze-Dried Plasma Product in the US
https://jamanetwork.com/journals/jama/fullarticle/2853282
The US Food and Drug Administration (FDA) approved the nation’s first freeze-dried plasma product.
https://jamanetwork.com/journals/jama/fullarticle/2853282
The US Food and Drug Administration (FDA) approved the nation’s first freeze-dried plasma product.
❤1
GLP-1 Drugs Linked to Lower Fracture Risk in People With Type 2 Diabetes
https://jamanetwork.com/journals/jama/fullarticle/2853281
Glucagon-like peptide-1 (GLP-1) receptor agonists may be associated with a lower risk of fragility fracture in patients with type 2 diabetes, a study published in JAMA Network Open found.
https://jamanetwork.com/journals/jama/fullarticle/2853281
Glucagon-like peptide-1 (GLP-1) receptor agonists may be associated with a lower risk of fragility fracture in patients with type 2 diabetes, a study published in JAMA Network Open found.
Conceptual Recognition of TAND
https://jamanetwork.com/journals/jamaneurology/fullarticle/2853088
The classification of neurodegenerative diseases increasingly incorporates underlying biology and pathology alongside clinical syndromes. This shift has been particularly evident in Alzheimer disease, where amyloid-β (Aβ) amyloid and tau biomarkers have changed both disease definitions and investigative methods. Similar developments have influenced the classification of other tauopathies and synucleinopathies. However, TAR DNA-binding protein 43 (TDP-43) proteinopathies present a difficult set of challenges, as TDP-43 pathology is observed in disorders that have traditionally been considered distinct clinical entities, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), limbic-predominant age-related TDP-43 encephalopathy (LATE), and inclusion body myositis (IBM). Although TDP-43 is well recognized as a major neurodegenerative proteinopathy, the issue raised by the term TDP-43–associated neurodegenerative disease (TAND) is whether a pathologic protein can represent an entire disease concept.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2853088
The classification of neurodegenerative diseases increasingly incorporates underlying biology and pathology alongside clinical syndromes. This shift has been particularly evident in Alzheimer disease, where amyloid-β (Aβ) amyloid and tau biomarkers have changed both disease definitions and investigative methods. Similar developments have influenced the classification of other tauopathies and synucleinopathies. However, TAR DNA-binding protein 43 (TDP-43) proteinopathies present a difficult set of challenges, as TDP-43 pathology is observed in disorders that have traditionally been considered distinct clinical entities, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), limbic-predominant age-related TDP-43 encephalopathy (LATE), and inclusion body myositis (IBM). Although TDP-43 is well recognized as a major neurodegenerative proteinopathy, the issue raised by the term TDP-43–associated neurodegenerative disease (TAND) is whether a pathologic protein can represent an entire disease concept.
De Novo Aneurysm Risk After Aneurysmal Subarachnoid Hemorrhage in Young Survivors
https://jamanetwork.com/journals/jamaneurology/fullarticle/2853087
This cohort study examines data across Swedish registries for young survivors of saccular aneurysmal subarachnoid hemorrhage to determine the lifetime cumulative incidence of, and factors associated with, radiologically detected de novo aneurysm formation.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2853087
This cohort study examines data across Swedish registries for young survivors of saccular aneurysmal subarachnoid hemorrhage to determine the lifetime cumulative incidence of, and factors associated with, radiologically detected de novo aneurysm formation.
TDP-43–Associated Neurodegenerative Disease
https://jamanetwork.com/journals/jamaneurology/fullarticle/2853086
This narrative review discusses an alternative approach to disease classification based on underlying pathobiology, specifically examining the role of transactive response DNA-binding protein, 43 kDa (TDP-43), pathology in neurodegenerative disorders, paving the way for the development of biomarkers and the advancement of therapeutic candidates that effectively target fundamental disease mechanisms.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2853086
This narrative review discusses an alternative approach to disease classification based on underlying pathobiology, specifically examining the role of transactive response DNA-binding protein, 43 kDa (TDP-43), pathology in neurodegenerative disorders, paving the way for the development of biomarkers and the advancement of therapeutic candidates that effectively target fundamental disease mechanisms.
Error in References
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852655
The Viewpoint, “Scientific Writing, Generative Artificial Intelligence, and the Non–Native English Speaker,” published in JAMA Internal Medicine online on May 18, 2026, and in the July 2026 issue, included 2 erroneous references. The author has explained that both are genuine sources but that errors were introduced when a generative artificial intelligence tool was used for reformatting references and when the DOI (digital object identifier) of a different version of a conference document was updated manually. The article has been corrected.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852655
The Viewpoint, “Scientific Writing, Generative Artificial Intelligence, and the Non–Native English Speaker,” published in JAMA Internal Medicine online on May 18, 2026, and in the July 2026 issue, included 2 erroneous references. The author has explained that both are genuine sources but that errors were introduced when a generative artificial intelligence tool was used for reformatting references and when the DOI (digital object identifier) of a different version of a conference document was updated manually. The article has been corrected.
Public Access to NIH-Funded Research Manuscripts
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852654
Health Care Policy
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852654
Health Care Policy
Nonreporting of Race and Ethnicity in Medical Research Harms Us All
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852653
At JAMA Internal Medicine, we have become increasingly aware that some US researchers are unable to report on race or ethnicity as demographic variables to describe their sample or to conduct stratified analyses by these variables. In some cases, we have been informed that based on 3 recent US federal executive orders, the stewards of federal databases, such as those responsible for distributing data from the Centers for Medicaid and Medicare Services (CMS), are unable to release any race or ethnicity data for research purposes. The restrictions may be particularly prohibitive when study investigators are US federal employees. We have been informed of similar concerns occurring at other biomedical journals. The potential for restricted access to race and ethnicity data across many federal databases has been highlighted, with disruptions reported during 2025 at the Behavioral Risk Factor Surveillance System (BRFSS) and other Centers for Disease Control and Prevention (CDC) databases, the US Census database, Health and Human Services (HHS), and National Institutes of Health (NIH) public use databases.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852653
At JAMA Internal Medicine, we have become increasingly aware that some US researchers are unable to report on race or ethnicity as demographic variables to describe their sample or to conduct stratified analyses by these variables. In some cases, we have been informed that based on 3 recent US federal executive orders, the stewards of federal databases, such as those responsible for distributing data from the Centers for Medicaid and Medicare Services (CMS), are unable to release any race or ethnicity data for research purposes. The restrictions may be particularly prohibitive when study investigators are US federal employees. We have been informed of similar concerns occurring at other biomedical journals. The potential for restricted access to race and ethnicity data across many federal databases has been highlighted, with disruptions reported during 2025 at the Behavioral Risk Factor Surveillance System (BRFSS) and other Centers for Disease Control and Prevention (CDC) databases, the US Census database, Health and Human Services (HHS), and National Institutes of Health (NIH) public use databases.
Rural-Urban Disparities in the Delivery and Intensity of the Medicare Hospice Benefit
https://jamanetwork.com/journals/jama/fullarticle/2853256
This cross-sectional study examines how hospice care varies across the rural-urban continuum, including length of stay, care setting, visits by hospice staff, and rates of higher-level care.
https://jamanetwork.com/journals/jama/fullarticle/2853256
This cross-sectional study examines how hospice care varies across the rural-urban continuum, including length of stay, care setting, visits by hospice staff, and rates of higher-level care.
Managing Chronic Subdural Hematoma
https://jamanetwork.com/journals/jama/fullarticle/2853255
To the Editor Interest in embolization of the middle meningeal artery (EMMA) for chronic subdural hematoma is growing, and the trial by Dr Shankar and colleagues is welcome. The decision to randomize patients to adjuvant embolization after surgical drainage is commendable because it preserves blinding of the surgeon and isolates the effect of embolization from variability in surgical performance.
https://jamanetwork.com/journals/jama/fullarticle/2853255
To the Editor Interest in embolization of the middle meningeal artery (EMMA) for chronic subdural hematoma is growing, and the trial by Dr Shankar and colleagues is welcome. The decision to randomize patients to adjuvant embolization after surgical drainage is commendable because it preserves blinding of the surgeon and isolates the effect of embolization from variability in surgical performance.
Managing Chronic Subdural Hematoma—Reply
https://jamanetwork.com/journals/jama/fullarticle/2853254
In Reply We thank Dr Madsbu and colleagues for their thoughtful comments regarding our trial and for highlighting the importance of optimizing surgical management in patients with chronic subdural hematoma.
https://jamanetwork.com/journals/jama/fullarticle/2853254
In Reply We thank Dr Madsbu and colleagues for their thoughtful comments regarding our trial and for highlighting the importance of optimizing surgical management in patients with chronic subdural hematoma.
Postural Orthostatic Tachycardia Syndrome
https://jamanetwork.com/journals/jama/fullarticle/2853253
This review summarizes current evidence on pathophysiology, diagnosis, and management of postural orthostatic tachycardia syndrome (POTS).
https://jamanetwork.com/journals/jama/fullarticle/2853253
This review summarizes current evidence on pathophysiology, diagnosis, and management of postural orthostatic tachycardia syndrome (POTS).
Health Care Ownership and Patient Care
https://jamanetwork.com/journals/jama/fullarticle/2853252
This Viewpoint discusses how consolidation in frontline care delivery has shaped health care markets across the US and how changes in ownership of hospitals and practices affect clinicians and patient outcomes.
https://jamanetwork.com/journals/jama/fullarticle/2853252
This Viewpoint discusses how consolidation in frontline care delivery has shaped health care markets across the US and how changes in ownership of hospitals and practices affect clinicians and patient outcomes.
Affiliations Updated
https://jamanetwork.com/journals/jama/fullarticle/2853317
The Original Investigation titled “Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023,” published July 29, 2026, was corrected to update the author affiliations list. This article was corrected online.
https://jamanetwork.com/journals/jama/fullarticle/2853317
The Original Investigation titled “Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023,” published July 29, 2026, was corrected to update the author affiliations list. This article was corrected online.